nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—ORM1—Vemurafenib—melanoma	0.168	0.307	CbGbCtD
Imipramine—ABCB1—melanoma	0.0989	1	CbGaD
Imipramine—CYP2E1—Dacarbazine—melanoma	0.0561	0.103	CbGbCtD
Imipramine—CYP1A2—Carmustine—melanoma	0.0536	0.0979	CbGbCtD
Imipramine—CYP1A2—Vemurafenib—melanoma	0.0423	0.0774	CbGbCtD
Imipramine—CYP3A4—Temozolomide—melanoma	0.0405	0.074	CbGbCtD
Imipramine—CYP2D6—Vemurafenib—melanoma	0.0349	0.0637	CbGbCtD
Imipramine—CYP1A2—Dacarbazine—melanoma	0.0325	0.0593	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.026	0.0476	CbGbCtD
Imipramine—CYP3A7—Docetaxel—melanoma	0.026	0.0476	CbGbCtD
Imipramine—ABCB1—Dactinomycin—melanoma	0.0246	0.045	CbGbCtD
Imipramine—CYP3A4—Vemurafenib—melanoma	0.0222	0.0405	CbGbCtD
Imipramine—ABCB1—Docetaxel—melanoma	0.0127	0.0232	CbGbCtD
Imipramine—CYP3A4—Docetaxel—melanoma	0.00761	0.0139	CbGbCtD
Imipramine—CHRM5—skin epidermis—melanoma	0.00196	0.0932	CbGeAlD
Imipramine—Olopatadine—S100B—melanoma	0.0018	0.376	CrCbGaD
Imipramine—Benazepril—SLC15A2—melanoma	0.000918	0.191	CrCbGaD
Imipramine—HTR2A—hindlimb—melanoma	0.000911	0.0434	CbGeAlD
Imipramine—HTR2A—appendage—melanoma	0.000781	0.0372	CbGeAlD
Imipramine—HTR7—endothelium—melanoma	0.000756	0.036	CbGeAlD
Imipramine—HTR7—blood vessel—melanoma	0.000698	0.0332	CbGeAlD
Imipramine—CHRM5—eye—melanoma	0.000697	0.0332	CbGeAlD
Imipramine—CYP2C18—mammalian vulva—melanoma	0.000677	0.0322	CbGeAlD
Imipramine—SLC22A4—neck—melanoma	0.000664	0.0316	CbGeAlD
Imipramine—Stomatitis—Bleomycin—melanoma	0.000638	0.00438	CcSEcCtD
Imipramine—KCND2—head—melanoma	0.00061	0.029	CbGeAlD
Imipramine—Pancytopenia—Carmustine—melanoma	0.000609	0.00418	CcSEcCtD
Imipramine—CHRM5—skin of body—melanoma	0.000607	0.0289	CbGeAlD
Imipramine—Decreased appetite—Vemurafenib—melanoma	0.000599	0.00411	CcSEcCtD
Imipramine—Stomatitis—Dactinomycin—melanoma	0.000595	0.00408	CcSEcCtD
Imipramine—Gastrointestinal disorder—Vemurafenib—melanoma	0.000595	0.00408	CcSEcCtD
Imipramine—Fatigue—Vemurafenib—melanoma	0.000594	0.00408	CcSEcCtD
Imipramine—Constipation—Vemurafenib—melanoma	0.00059	0.00404	CcSEcCtD
Imipramine—Pancytopenia—Temozolomide—melanoma	0.000589	0.00403	CcSEcCtD
Imipramine—Hypoaesthesia—Bleomycin—melanoma	0.000585	0.00401	CcSEcCtD
Imipramine—Pollakiuria—Temozolomide—melanoma	0.000572	0.00392	CcSEcCtD
Imipramine—Erectile dysfunction—Temozolomide—melanoma	0.000571	0.00391	CcSEcCtD
Imipramine—Agranulocytosis—Dactinomycin—melanoma	0.00057	0.00391	CcSEcCtD
Imipramine—Photosensitivity reaction—Temozolomide—melanoma	0.000566	0.00388	CcSEcCtD
Imipramine—Weight increased—Temozolomide—melanoma	0.000564	0.00387	CcSEcCtD
Imipramine—Weight decreased—Temozolomide—melanoma	0.000561	0.00384	CcSEcCtD
Imipramine—Neuropathy peripheral—Carmustine—melanoma	0.00056	0.00384	CcSEcCtD
Imipramine—Stomatitis—Carmustine—melanoma	0.000557	0.00382	CcSEcCtD
Imipramine—Infestation NOS—Temozolomide—melanoma	0.000553	0.00379	CcSEcCtD
Imipramine—Infestation—Temozolomide—melanoma	0.000553	0.00379	CcSEcCtD
Imipramine—Hepatitis—Dactinomycin—melanoma	0.000548	0.00376	CcSEcCtD
Imipramine—Flushing—Bleomycin—melanoma	0.000546	0.00374	CcSEcCtD
Imipramine—Body temperature increased—Vemurafenib—melanoma	0.000545	0.00374	CcSEcCtD
Imipramine—Neuropathy peripheral—Temozolomide—melanoma	0.000542	0.00371	CcSEcCtD
Imipramine—Stomatitis—Temozolomide—melanoma	0.000539	0.00369	CcSEcCtD
Imipramine—KCND3—head—melanoma	0.000532	0.0253	CbGeAlD
Imipramine—Cardiac failure congestive—Docetaxel—melanoma	0.000526	0.0036	CcSEcCtD
Imipramine—Hepatobiliary disease—Temozolomide—melanoma	0.000523	0.00358	CcSEcCtD
Imipramine—Alopecia—Bleomycin—melanoma	0.00052	0.00356	CcSEcCtD
Imipramine—Hypoaesthesia—Carmustine—melanoma	0.000511	0.0035	CcSEcCtD
Imipramine—Hallucination—Carmustine—melanoma	0.000511	0.0035	CcSEcCtD
Imipramine—Hot flush—Docetaxel—melanoma	0.00051	0.00349	CcSEcCtD
Imipramine—Flushing—Dactinomycin—melanoma	0.000509	0.00349	CcSEcCtD
Imipramine—CHRM4—head—melanoma	0.000507	0.0241	CbGeAlD
Imipramine—Menopausal symptoms—Docetaxel—melanoma	0.000505	0.00346	CcSEcCtD
Imipramine—HTR7—neck—melanoma	0.000499	0.0238	CbGeAlD
Imipramine—Hepatitis—Temozolomide—melanoma	0.000496	0.0034	CcSEcCtD
Imipramine—Asthenia—Vemurafenib—melanoma	0.000495	0.00339	CcSEcCtD
Imipramine—Hallucination—Temozolomide—melanoma	0.000494	0.00338	CcSEcCtD
Imipramine—Hypoaesthesia—Temozolomide—melanoma	0.000494	0.00338	CcSEcCtD
Imipramine—Urinary tract disorder—Temozolomide—melanoma	0.00049	0.00336	CcSEcCtD
Imipramine—Cardiac failure—Docetaxel—melanoma	0.000489	0.00335	CcSEcCtD
Imipramine—Pruritus—Vemurafenib—melanoma	0.000488	0.00334	CcSEcCtD
Imipramine—Urethral disorder—Temozolomide—melanoma	0.000486	0.00333	CcSEcCtD
Imipramine—Alopecia—Dactinomycin—melanoma	0.000485	0.00332	CcSEcCtD
Imipramine—Eye disorder—Carmustine—melanoma	0.00048	0.00329	CcSEcCtD
Imipramine—Flushing—Carmustine—melanoma	0.000476	0.00327	CcSEcCtD
Imipramine—Ill-defined disorder—Bleomycin—melanoma	0.000475	0.00326	CcSEcCtD
Imipramine—Diarrhoea—Vemurafenib—melanoma	0.000472	0.00323	CcSEcCtD
Imipramine—HTR2A—endothelium—melanoma	0.000472	0.0225	CbGeAlD
Imipramine—Eye disorder—Temozolomide—melanoma	0.000464	0.00318	CcSEcCtD
Imipramine—Tinnitus—Temozolomide—melanoma	0.000462	0.00317	CcSEcCtD
Imipramine—Malaise—Bleomycin—melanoma	0.000462	0.00316	CcSEcCtD
Imipramine—Flushing—Temozolomide—melanoma	0.00046	0.00316	CcSEcCtD
Imipramine—Cardiac disorder—Temozolomide—melanoma	0.00046	0.00316	CcSEcCtD
Imipramine—Arrhythmia—Carmustine—melanoma	0.000459	0.00314	CcSEcCtD
Imipramine—Leukopenia—Bleomycin—melanoma	0.000458	0.00314	CcSEcCtD
Imipramine—Dizziness—Vemurafenib—melanoma	0.000456	0.00313	CcSEcCtD
Imipramine—Alopecia—Carmustine—melanoma	0.000454	0.00311	CcSEcCtD
Imipramine—HTR6—head—melanoma	0.000453	0.0216	CbGeAlD
Imipramine—Angiopathy—Temozolomide—melanoma	0.00045	0.00309	CcSEcCtD
Imipramine—Mental disorder—Carmustine—melanoma	0.00045	0.00308	CcSEcCtD
Imipramine—Ataxia—Docetaxel—melanoma	0.000448	0.00307	CcSEcCtD
Imipramine—Immune system disorder—Temozolomide—melanoma	0.000448	0.00307	CcSEcCtD
Imipramine—Mediastinal disorder—Temozolomide—melanoma	0.000447	0.00306	CcSEcCtD
Imipramine—Malnutrition—Carmustine—melanoma	0.000447	0.00306	CcSEcCtD
Imipramine—Ill-defined disorder—Dactinomycin—melanoma	0.000443	0.00304	CcSEcCtD
Imipramine—Liver function test abnormal—Docetaxel—melanoma	0.00044	0.00302	CcSEcCtD
Imipramine—Vomiting—Vemurafenib—melanoma	0.000438	0.00301	CcSEcCtD
Imipramine—Alopecia—Temozolomide—melanoma	0.000438	0.003	CcSEcCtD
Imipramine—Orthostatic hypotension—Docetaxel—melanoma	0.000435	0.00299	CcSEcCtD
Imipramine—HTR2A—blood vessel—melanoma	0.000435	0.0207	CbGeAlD
Imipramine—Rash—Vemurafenib—melanoma	0.000435	0.00298	CcSEcCtD
Imipramine—Mental disorder—Temozolomide—melanoma	0.000435	0.00298	CcSEcCtD
Imipramine—Dermatitis—Vemurafenib—melanoma	0.000434	0.00298	CcSEcCtD
Imipramine—Headache—Vemurafenib—melanoma	0.000432	0.00296	CcSEcCtD
Imipramine—Malnutrition—Temozolomide—melanoma	0.000432	0.00296	CcSEcCtD
Imipramine—Breast disorder—Docetaxel—melanoma	0.000431	0.00295	CcSEcCtD
Imipramine—Discomfort—Bleomycin—melanoma	0.000431	0.00295	CcSEcCtD
Imipramine—Malaise—Dactinomycin—melanoma	0.000431	0.00295	CcSEcCtD
Imipramine—Leukopenia—Dactinomycin—melanoma	0.000427	0.00293	CcSEcCtD
Imipramine—Dysgeusia—Temozolomide—melanoma	0.000423	0.0029	CcSEcCtD
Imipramine—Confusional state—Bleomycin—melanoma	0.000421	0.00289	CcSEcCtD
Imipramine—Vision blurred—Carmustine—melanoma	0.000421	0.00289	CcSEcCtD
Imipramine—Tremor—Carmustine—melanoma	0.000419	0.00287	CcSEcCtD
Imipramine—Oedema—Bleomycin—melanoma	0.000418	0.00286	CcSEcCtD
Imipramine—Anaphylactic shock—Bleomycin—melanoma	0.000418	0.00286	CcSEcCtD
Imipramine—Infection—Bleomycin—melanoma	0.000415	0.00285	CcSEcCtD
Imipramine—Agitation—Carmustine—melanoma	0.000411	0.00281	CcSEcCtD
Imipramine—Nausea—Vemurafenib—melanoma	0.00041	0.00281	CcSEcCtD
Imipramine—Thrombocytopenia—Bleomycin—melanoma	0.000409	0.0028	CcSEcCtD
Imipramine—Vision blurred—Temozolomide—melanoma	0.000407	0.00279	CcSEcCtD
Imipramine—Tremor—Temozolomide—melanoma	0.000405	0.00277	CcSEcCtD
Imipramine—Discomfort—Dactinomycin—melanoma	0.000402	0.00275	CcSEcCtD
Imipramine—Ill-defined disorder—Temozolomide—melanoma	0.000401	0.00275	CcSEcCtD
Imipramine—Leukopenia—Carmustine—melanoma	0.0004	0.00274	CcSEcCtD
Imipramine—Anorexia—Bleomycin—melanoma	0.000398	0.00273	CcSEcCtD
Imipramine—Agitation—Temozolomide—melanoma	0.000397	0.00272	CcSEcCtD
Imipramine—CHRM5—head—melanoma	0.000396	0.0188	CbGeAlD
Imipramine—Pancytopenia—Docetaxel—melanoma	0.000391	0.00268	CcSEcCtD
Imipramine—Oedema—Dactinomycin—melanoma	0.00039	0.00267	CcSEcCtD
Imipramine—Malaise—Temozolomide—melanoma	0.000389	0.00267	CcSEcCtD
Imipramine—Convulsion—Carmustine—melanoma	0.000387	0.00265	CcSEcCtD
Imipramine—Infection—Dactinomycin—melanoma	0.000387	0.00265	CcSEcCtD
Imipramine—Leukopenia—Temozolomide—melanoma	0.000387	0.00265	CcSEcCtD
Imipramine—Hypertension—Carmustine—melanoma	0.000386	0.00264	CcSEcCtD
Imipramine—Palpitations—Temozolomide—melanoma	0.000382	0.00262	CcSEcCtD
Imipramine—Thrombocytopenia—Dactinomycin—melanoma	0.000381	0.00262	CcSEcCtD
Imipramine—Anxiety—Carmustine—melanoma	0.000379	0.0026	CcSEcCtD
Imipramine—Paraesthesia—Bleomycin—melanoma	0.000375	0.00257	CcSEcCtD
Imipramine—Weight increased—Docetaxel—melanoma	0.000375	0.00257	CcSEcCtD
Imipramine—Convulsion—Temozolomide—melanoma	0.000374	0.00256	CcSEcCtD
Imipramine—Weight decreased—Docetaxel—melanoma	0.000373	0.00256	CcSEcCtD
Imipramine—Hypertension—Temozolomide—melanoma	0.000373	0.00256	CcSEcCtD
Imipramine—KCND3—lymph node—melanoma	0.000372	0.0177	CbGeAlD
Imipramine—Anorexia—Dactinomycin—melanoma	0.000371	0.00255	CcSEcCtD
Imipramine—Confusional state—Carmustine—melanoma	0.000368	0.00252	CcSEcCtD
Imipramine—Infestation NOS—Docetaxel—melanoma	0.000367	0.00252	CcSEcCtD
Imipramine—Infestation—Docetaxel—melanoma	0.000367	0.00252	CcSEcCtD
Imipramine—Anxiety—Temozolomide—melanoma	0.000366	0.00251	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000365	0.0025	CcSEcCtD
Imipramine—Oedema—Carmustine—melanoma	0.000365	0.0025	CcSEcCtD
Imipramine—Discomfort—Temozolomide—melanoma	0.000363	0.00249	CcSEcCtD
Imipramine—Decreased appetite—Bleomycin—melanoma	0.000363	0.00249	CcSEcCtD
Imipramine—Infection—Carmustine—melanoma	0.000362	0.00248	CcSEcCtD
Imipramine—Acute coronary syndrome—Docetaxel—melanoma	0.000362	0.00248	CcSEcCtD
Imipramine—ADRA1B—head—melanoma	0.000362	0.0172	CbGeAlD
Imipramine—Myocardial infarction—Docetaxel—melanoma	0.00036	0.00247	CcSEcCtD
Imipramine—Neuropathy peripheral—Docetaxel—melanoma	0.00036	0.00247	CcSEcCtD
Imipramine—Dry mouth—Temozolomide—melanoma	0.00036	0.00246	CcSEcCtD
Imipramine—Jaundice—Docetaxel—melanoma	0.000358	0.00246	CcSEcCtD
Imipramine—Stomatitis—Docetaxel—melanoma	0.000358	0.00246	CcSEcCtD
Imipramine—Thrombocytopenia—Carmustine—melanoma	0.000357	0.00245	CcSEcCtD
Imipramine—SLC22A3—mammalian vulva—melanoma	0.000357	0.017	CbGeAlD
Imipramine—Tachycardia—Carmustine—melanoma	0.000356	0.00244	CcSEcCtD
Imipramine—Confusional state—Temozolomide—melanoma	0.000355	0.00244	CcSEcCtD
Imipramine—ADRA1D—head—melanoma	0.000354	0.0168	CbGeAlD
Imipramine—Anaphylactic shock—Temozolomide—melanoma	0.000352	0.00242	CcSEcCtD
Imipramine—Oedema—Temozolomide—melanoma	0.000352	0.00242	CcSEcCtD
Imipramine—DRD2—eye—melanoma	0.000351	0.0167	CbGeAlD
Imipramine—Infection—Temozolomide—melanoma	0.00035	0.0024	CcSEcCtD
Imipramine—DRD2—retina—melanoma	0.000348	0.0166	CbGeAlD
Imipramine—Anorexia—Carmustine—melanoma	0.000348	0.00238	CcSEcCtD
Imipramine—Hepatobiliary disease—Docetaxel—melanoma	0.000348	0.00238	CcSEcCtD
Imipramine—Nervous system disorder—Temozolomide—melanoma	0.000346	0.00237	CcSEcCtD
Imipramine—Thrombocytopenia—Temozolomide—melanoma	0.000345	0.00237	CcSEcCtD
Imipramine—Feeling abnormal—Bleomycin—melanoma	0.000344	0.00236	CcSEcCtD
Imipramine—Agranulocytosis—Docetaxel—melanoma	0.000343	0.00235	CcSEcCtD
Imipramine—Skin disorder—Temozolomide—melanoma	0.000342	0.00235	CcSEcCtD
Imipramine—Hyperhidrosis—Temozolomide—melanoma	0.000341	0.00234	CcSEcCtD
Imipramine—Decreased appetite—Dactinomycin—melanoma	0.000339	0.00232	CcSEcCtD
Imipramine—Fatigue—Dactinomycin—melanoma	0.000336	0.0023	CcSEcCtD
Imipramine—Anorexia—Temozolomide—melanoma	0.000336	0.0023	CcSEcCtD
Imipramine—Urticaria—Bleomycin—melanoma	0.000332	0.00228	CcSEcCtD
Imipramine—Body temperature increased—Bleomycin—melanoma	0.00033	0.00226	CcSEcCtD
Imipramine—Hepatitis—Docetaxel—melanoma	0.00033	0.00226	CcSEcCtD
Imipramine—Insomnia—Carmustine—melanoma	0.00033	0.00226	CcSEcCtD
Imipramine—Hypoaesthesia—Docetaxel—melanoma	0.000328	0.00225	CcSEcCtD
Imipramine—Paraesthesia—Carmustine—melanoma	0.000327	0.00224	CcSEcCtD
Imipramine—Urinary tract disorder—Docetaxel—melanoma	0.000326	0.00223	CcSEcCtD
Imipramine—Somnolence—Carmustine—melanoma	0.000324	0.00222	CcSEcCtD
Imipramine—Urethral disorder—Docetaxel—melanoma	0.000323	0.00222	CcSEcCtD
Imipramine—Feeling abnormal—Dactinomycin—melanoma	0.000321	0.0022	CcSEcCtD
Imipramine—Orphenadrine—SCN10A—melanoma	0.00032	0.0668	CrCbGaD
Imipramine—Insomnia—Temozolomide—melanoma	0.000319	0.00219	CcSEcCtD
Imipramine—Gastrointestinal pain—Dactinomycin—melanoma	0.000319	0.00218	CcSEcCtD
Imipramine—Decreased appetite—Carmustine—melanoma	0.000317	0.00217	CcSEcCtD
Imipramine—Paraesthesia—Temozolomide—melanoma	0.000316	0.00217	CcSEcCtD
Imipramine—Gastrointestinal disorder—Carmustine—melanoma	0.000315	0.00216	CcSEcCtD
Imipramine—Somnolence—Temozolomide—melanoma	0.000313	0.00215	CcSEcCtD
Imipramine—Constipation—Carmustine—melanoma	0.000312	0.00214	CcSEcCtD
Imipramine—HTR2A—neck—melanoma	0.000311	0.0148	CbGeAlD
Imipramine—Dyspepsia—Temozolomide—melanoma	0.00031	0.00213	CcSEcCtD
Imipramine—Eye disorder—Docetaxel—melanoma	0.000308	0.00211	CcSEcCtD
Imipramine—Abdominal pain—Dactinomycin—melanoma	0.000308	0.00211	CcSEcCtD
Imipramine—Body temperature increased—Dactinomycin—melanoma	0.000308	0.00211	CcSEcCtD
Imipramine—Decreased appetite—Temozolomide—melanoma	0.000306	0.0021	CcSEcCtD
Imipramine—Cardiac disorder—Docetaxel—melanoma	0.000306	0.0021	CcSEcCtD
Imipramine—Flushing—Docetaxel—melanoma	0.000306	0.0021	CcSEcCtD
Imipramine—Gastrointestinal disorder—Temozolomide—melanoma	0.000304	0.00209	CcSEcCtD
Imipramine—Fatigue—Temozolomide—melanoma	0.000304	0.00208	CcSEcCtD
Imipramine—Constipation—Temozolomide—melanoma	0.000301	0.00207	CcSEcCtD
Imipramine—Feeling abnormal—Carmustine—melanoma	0.000301	0.00206	CcSEcCtD
Imipramine—Asthenia—Bleomycin—melanoma	0.0003	0.00205	CcSEcCtD
Imipramine—Angiopathy—Docetaxel—melanoma	0.000299	0.00205	CcSEcCtD
Imipramine—Gastrointestinal pain—Carmustine—melanoma	0.000298	0.00204	CcSEcCtD
Imipramine—Immune system disorder—Docetaxel—melanoma	0.000298	0.00204	CcSEcCtD
Imipramine—Mediastinal disorder—Docetaxel—melanoma	0.000297	0.00204	CcSEcCtD
Imipramine—Pruritus—Bleomycin—melanoma	0.000296	0.00203	CcSEcCtD
Imipramine—Arrhythmia—Docetaxel—melanoma	0.000295	0.00202	CcSEcCtD
Imipramine—Alopecia—Docetaxel—melanoma	0.000291	0.002	CcSEcCtD
Imipramine—Feeling abnormal—Temozolomide—melanoma	0.00029	0.00199	CcSEcCtD
Imipramine—Mental disorder—Docetaxel—melanoma	0.000289	0.00198	CcSEcCtD
Imipramine—Abdominal pain—Carmustine—melanoma	0.000288	0.00198	CcSEcCtD
Imipramine—Body temperature increased—Carmustine—melanoma	0.000288	0.00198	CcSEcCtD
Imipramine—Gastrointestinal pain—Temozolomide—melanoma	0.000288	0.00198	CcSEcCtD
Imipramine—Malnutrition—Docetaxel—melanoma	0.000287	0.00197	CcSEcCtD
Imipramine—ABCB1—blood vessel—melanoma	0.000285	0.0136	CbGeAlD
Imipramine—Dysgeusia—Docetaxel—melanoma	0.000281	0.00193	CcSEcCtD
Imipramine—Urticaria—Temozolomide—melanoma	0.00028	0.00192	CcSEcCtD
Imipramine—Asthenia—Dactinomycin—melanoma	0.00028	0.00192	CcSEcCtD
Imipramine—Body temperature increased—Temozolomide—melanoma	0.000279	0.00191	CcSEcCtD
Imipramine—Abdominal pain—Temozolomide—melanoma	0.000279	0.00191	CcSEcCtD
Imipramine—HRH1—eye—melanoma	0.000277	0.0132	CbGeAlD
Imipramine—CHRM2—head—melanoma	0.000272	0.0129	CbGeAlD
Imipramine—SLC6A3—head—melanoma	0.000271	0.0129	CbGeAlD
Imipramine—SLC22A1—head—melanoma	0.000267	0.0127	CbGeAlD
Imipramine—Diarrhoea—Dactinomycin—melanoma	0.000267	0.00183	CcSEcCtD
Imipramine—Vomiting—Bleomycin—melanoma	0.000266	0.00182	CcSEcCtD
Imipramine—Rash—Bleomycin—melanoma	0.000263	0.00181	CcSEcCtD
Imipramine—Dermatitis—Bleomycin—melanoma	0.000263	0.0018	CcSEcCtD
Imipramine—HTR2C—head—melanoma	0.000262	0.0125	CbGeAlD
Imipramine—Asthenia—Carmustine—melanoma	0.000262	0.00179	CcSEcCtD
Imipramine—Syncope—Docetaxel—melanoma	0.000258	0.00177	CcSEcCtD
Imipramine—Leukopenia—Docetaxel—melanoma	0.000257	0.00176	CcSEcCtD
Imipramine—SLC22A3—head—melanoma	0.000255	0.0121	CbGeAlD
Imipramine—Palpitations—Docetaxel—melanoma	0.000254	0.00174	CcSEcCtD
Imipramine—Asthenia—Temozolomide—melanoma	0.000253	0.00173	CcSEcCtD
Imipramine—Loss of consciousness—Docetaxel—melanoma	0.000252	0.00173	CcSEcCtD
Imipramine—Diarrhoea—Carmustine—melanoma	0.00025	0.00171	CcSEcCtD
Imipramine—Pruritus—Temozolomide—melanoma	0.000249	0.00171	CcSEcCtD
Imipramine—Convulsion—Docetaxel—melanoma	0.000249	0.00171	CcSEcCtD
Imipramine—SLC6A4—head—melanoma	0.000248	0.0118	CbGeAlD
Imipramine—Nausea—Bleomycin—melanoma	0.000248	0.0017	CcSEcCtD
Imipramine—Hypertension—Docetaxel—melanoma	0.000248	0.0017	CcSEcCtD
Imipramine—Vomiting—Dactinomycin—melanoma	0.000248	0.0017	CcSEcCtD
Imipramine—CHRM1—head—melanoma	0.000247	0.0118	CbGeAlD
Imipramine—CYP2B6—skin of body—melanoma	0.000247	0.0118	CbGeAlD
Imipramine—Rash—Dactinomycin—melanoma	0.000246	0.00168	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000243	0.00166	CcSEcCtD
Imipramine—Dizziness—Carmustine—melanoma	0.000241	0.00165	CcSEcCtD
Imipramine—Diarrhoea—Temozolomide—melanoma	0.000241	0.00165	CcSEcCtD
Imipramine—Dry mouth—Docetaxel—melanoma	0.000239	0.00164	CcSEcCtD
Imipramine—Confusional state—Docetaxel—melanoma	0.000236	0.00162	CcSEcCtD
Imipramine—Oedema—Docetaxel—melanoma	0.000234	0.00161	CcSEcCtD
Imipramine—Anaphylactic shock—Docetaxel—melanoma	0.000234	0.00161	CcSEcCtD
Imipramine—Dizziness—Temozolomide—melanoma	0.000233	0.0016	CcSEcCtD
Imipramine—Infection—Docetaxel—melanoma	0.000233	0.0016	CcSEcCtD
Imipramine—Vomiting—Carmustine—melanoma	0.000232	0.00159	CcSEcCtD
Imipramine—HTR2A—eye—melanoma	0.000231	0.011	CbGeAlD
Imipramine—Nausea—Dactinomycin—melanoma	0.000231	0.00159	CcSEcCtD
Imipramine—Shock—Docetaxel—melanoma	0.000231	0.00158	CcSEcCtD
Imipramine—Rash—Carmustine—melanoma	0.00023	0.00158	CcSEcCtD
Imipramine—Nervous system disorder—Docetaxel—melanoma	0.00023	0.00158	CcSEcCtD
Imipramine—Dermatitis—Carmustine—melanoma	0.00023	0.00157	CcSEcCtD
Imipramine—Thrombocytopenia—Docetaxel—melanoma	0.000229	0.00157	CcSEcCtD
Imipramine—HTR2A—retina—melanoma	0.000229	0.0109	CbGeAlD
Imipramine—Tachycardia—Docetaxel—melanoma	0.000229	0.00157	CcSEcCtD
Imipramine—Headache—Carmustine—melanoma	0.000228	0.00157	CcSEcCtD
Imipramine—Skin disorder—Docetaxel—melanoma	0.000228	0.00156	CcSEcCtD
Imipramine—Vomiting—Temozolomide—melanoma	0.000224	0.00154	CcSEcCtD
Imipramine—Anorexia—Docetaxel—melanoma	0.000223	0.00153	CcSEcCtD
Imipramine—Rash—Temozolomide—melanoma	0.000222	0.00152	CcSEcCtD
Imipramine—Dermatitis—Temozolomide—melanoma	0.000222	0.00152	CcSEcCtD
Imipramine—CHRM3—head—melanoma	0.000221	0.0105	CbGeAlD
Imipramine—Headache—Temozolomide—melanoma	0.000221	0.00151	CcSEcCtD
Imipramine—HTR1A—head—melanoma	0.00022	0.0105	CbGeAlD
Imipramine—HRH1—mammalian vulva—melanoma	0.00022	0.0105	CbGeAlD
Imipramine—SLC6A2—head—melanoma	0.000219	0.0104	CbGeAlD
Imipramine—Nausea—Carmustine—melanoma	0.000217	0.00148	CcSEcCtD
Imipramine—Insomnia—Docetaxel—melanoma	0.000212	0.00145	CcSEcCtD
Imipramine—HTR7—head—melanoma	0.000211	0.01	CbGeAlD
Imipramine—Paraesthesia—Docetaxel—melanoma	0.00021	0.00144	CcSEcCtD
Imipramine—Nausea—Temozolomide—melanoma	0.000209	0.00144	CcSEcCtD
Imipramine—Somnolence—Docetaxel—melanoma	0.000208	0.00143	CcSEcCtD
Imipramine—Dyspepsia—Docetaxel—melanoma	0.000206	0.00141	CcSEcCtD
Imipramine—ORM1—lymph node—melanoma	0.000204	0.00971	CbGeAlD
Imipramine—Decreased appetite—Docetaxel—melanoma	0.000204	0.0014	CcSEcCtD
Imipramine—ADRA1A—head—melanoma	0.000203	0.00967	CbGeAlD
Imipramine—Gastrointestinal disorder—Docetaxel—melanoma	0.000202	0.00139	CcSEcCtD
Imipramine—Fatigue—Docetaxel—melanoma	0.000202	0.00139	CcSEcCtD
Imipramine—Constipation—Docetaxel—melanoma	0.0002	0.00137	CcSEcCtD
Imipramine—DRD2—head—melanoma	0.000199	0.00948	CbGeAlD
Imipramine—SLC22A4—lymph node—melanoma	0.000196	0.00934	CbGeAlD
Imipramine—KCNH2—head—melanoma	0.000196	0.00934	CbGeAlD
Imipramine—Feeling abnormal—Docetaxel—melanoma	0.000193	0.00132	CcSEcCtD
Imipramine—Gastrointestinal pain—Docetaxel—melanoma	0.000192	0.00131	CcSEcCtD
Imipramine—Abdominal pain—Docetaxel—melanoma	0.000185	0.00127	CcSEcCtD
Imipramine—Body temperature increased—Docetaxel—melanoma	0.000185	0.00127	CcSEcCtD
Imipramine—SLC22A3—lymph node—melanoma	0.000179	0.0085	CbGeAlD
Imipramine—Asthenia—Docetaxel—melanoma	0.000168	0.00115	CcSEcCtD
Imipramine—Pruritus—Docetaxel—melanoma	0.000166	0.00114	CcSEcCtD
Imipramine—CYP2B6—head—melanoma	0.000161	0.00767	CbGeAlD
Imipramine—Diarrhoea—Docetaxel—melanoma	0.00016	0.0011	CcSEcCtD
Imipramine—HRH1—head—melanoma	0.000157	0.00749	CbGeAlD
Imipramine—Epinastine—ABCB1—melanoma	0.000155	0.0324	CrCbGaD
Imipramine—Dizziness—Docetaxel—melanoma	0.000155	0.00106	CcSEcCtD
Imipramine—SLC6A2—lymph node—melanoma	0.000153	0.00729	CbGeAlD
Imipramine—CYP2E1—head—melanoma	0.000151	0.0072	CbGeAlD
Imipramine—ABCB1—retina—melanoma	0.00015	0.00716	CbGeAlD
Imipramine—Oxcarbazepine—ALB—melanoma	0.00015	0.0313	CrCbGaD
Imipramine—Vomiting—Docetaxel—melanoma	0.000149	0.00102	CcSEcCtD
Imipramine—Rash—Docetaxel—melanoma	0.000148	0.00101	CcSEcCtD
Imipramine—Dermatitis—Docetaxel—melanoma	0.000148	0.00101	CcSEcCtD
Imipramine—Headache—Docetaxel—melanoma	0.000147	0.00101	CcSEcCtD
Imipramine—Nausea—Docetaxel—melanoma	0.000139	0.000954	CcSEcCtD
Imipramine—KCNH2—lymph node—melanoma	0.000137	0.00654	CbGeAlD
Imipramine—Maprotiline—ABCB1—melanoma	0.000134	0.0279	CrCbGaD
Imipramine—HTR2A—head—melanoma	0.000131	0.00625	CbGeAlD
Imipramine—ABCB1—mammalian vulva—melanoma	0.00012	0.00573	CbGeAlD
Imipramine—CYP2D6—head—melanoma	0.00012	0.0057	CbGeAlD
Imipramine—Triflupromazine—ABCB1—melanoma	0.000117	0.0244	CrCbGaD
Imipramine—Acepromazine—ALB—melanoma	0.000113	0.0236	CrCbGaD
Imipramine—Thioproperazine—ALB—melanoma	0.000111	0.0231	CrCbGaD
Imipramine—HRH1—lymph node—melanoma	0.00011	0.00524	CbGeAlD
Imipramine—Pipotiazine—ALB—melanoma	0.000109	0.0227	CrCbGaD
Imipramine—Carbamazepine—ABCB1—melanoma	9.76e-05	0.0203	CrCbGaD
Imipramine—Clomipramine—ALB—melanoma	8.62e-05	0.018	CrCbGaD
Imipramine—ABCB1—head—melanoma	8.61e-05	0.0041	CbGeAlD
Imipramine—Nortriptyline—ALB—melanoma	8.42e-05	0.0176	CrCbGaD
Imipramine—Clomipramine—ABCB1—melanoma	8.23e-05	0.0171	CrCbGaD
Imipramine—Trimipramine—ABCB1—melanoma	7.57e-05	0.0158	CrCbGaD
Imipramine—Promethazine—ABCB1—melanoma	7.29e-05	0.0152	CrCbGaD
Imipramine—Doxepin—ABCB1—melanoma	7.21e-05	0.015	CrCbGaD
Imipramine—Desipramine—ABCB1—melanoma	6.62e-05	0.0138	CrCbGaD
Imipramine—ABCB1—lymph node—melanoma	6.03e-05	0.00287	CbGeAlD
Imipramine—Chlorpromazine—ALB—melanoma	5.91e-05	0.0123	CrCbGaD
Imipramine—Amitriptyline—ALB—melanoma	5.85e-05	0.0122	CrCbGaD
Imipramine—Chlorpromazine—ABCB1—melanoma	5.64e-05	0.0118	CrCbGaD
Imipramine—Amitriptyline—ABCB1—melanoma	5.58e-05	0.0116	CrCbGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—melanoma	3.04e-06	1.67e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—melanoma	3.04e-06	1.67e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STAT3—melanoma	3.04e-06	1.67e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—melanoma	3.03e-06	1.66e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—melanoma	3.03e-06	1.66e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CTNNB1—melanoma	3.02e-06	1.66e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CTNNB1—melanoma	3.02e-06	1.66e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CD—melanoma	3.02e-06	1.66e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CTNNB1—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—melanoma	3.01e-06	1.65e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CDKN1A—melanoma	3e-06	1.65e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CTNNB1—melanoma	3e-06	1.65e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—melanoma	3e-06	1.65e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—melanoma	3e-06	1.64e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—melanoma	2.99e-06	1.64e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NFKB1—melanoma	2.98e-06	1.64e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ALB—melanoma	2.98e-06	1.64e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CTNNB1—melanoma	2.97e-06	1.63e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—melanoma	2.97e-06	1.63e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—melanoma	2.97e-06	1.63e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	2.96e-06	1.63e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—melanoma	2.96e-06	1.62e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CDKN1A—melanoma	2.96e-06	1.62e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—melanoma	2.95e-06	1.62e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CDKN1A—melanoma	2.95e-06	1.62e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—melanoma	2.95e-06	1.62e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—melanoma	2.95e-06	1.62e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CD—melanoma	2.95e-06	1.62e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—melanoma	2.94e-06	1.61e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—melanoma	2.94e-06	1.61e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CDKN1A—melanoma	2.94e-06	1.61e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—melanoma	2.94e-06	1.61e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—melanoma	2.94e-06	1.61e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NFKB1—melanoma	2.93e-06	1.61e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—melanoma	2.93e-06	1.61e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CDKN1A—melanoma	2.93e-06	1.61e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NFKB1—melanoma	2.93e-06	1.61e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—melanoma	2.92e-06	1.6e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—melanoma	2.92e-06	1.6e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NFKB1—melanoma	2.92e-06	1.6e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK3—melanoma	2.92e-06	1.6e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—melanoma	2.91e-06	1.6e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NFKB1—melanoma	2.91e-06	1.6e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ALB—melanoma	2.91e-06	1.6e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—melanoma	2.91e-06	1.6e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—melanoma	2.9e-06	1.59e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CDKN1A—melanoma	2.9e-06	1.59e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK3—melanoma	2.9e-06	1.59e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—melanoma	2.9e-06	1.59e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—melanoma	2.89e-06	1.59e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	2.89e-06	1.59e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—melanoma	2.89e-06	1.58e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NFKB1—melanoma	2.88e-06	1.58e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—melanoma	2.88e-06	1.58e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—melanoma	2.88e-06	1.58e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—melanoma	2.88e-06	1.58e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NFKB1—melanoma	2.87e-06	1.58e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—melanoma	2.87e-06	1.58e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—melanoma	2.87e-06	1.57e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—melanoma	2.86e-06	1.57e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ABCB1—melanoma	2.86e-06	1.57e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—melanoma	2.86e-06	1.57e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—melanoma	2.85e-06	1.57e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—melanoma	2.84e-06	1.56e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—melanoma	2.84e-06	1.56e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—melanoma	2.84e-06	1.56e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—melanoma	2.82e-06	1.55e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—melanoma	2.82e-06	1.55e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—melanoma	2.82e-06	1.55e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.81e-06	1.54e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK3—melanoma	2.78e-06	1.52e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CD—melanoma	2.78e-06	1.52e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK1—melanoma	2.77e-06	1.52e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—melanoma	2.77e-06	1.52e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	2.76e-06	1.52e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK1—melanoma	2.76e-06	1.52e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—melanoma	2.76e-06	1.51e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ALB—melanoma	2.74e-06	1.5e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—melanoma	2.72e-06	1.49e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—melanoma	2.72e-06	1.49e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—melanoma	2.71e-06	1.49e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—melanoma	2.7e-06	1.48e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—melanoma	2.68e-06	1.47e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CG—melanoma	2.67e-06	1.47e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—melanoma	2.67e-06	1.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—melanoma	2.67e-06	1.47e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—melanoma	2.67e-06	1.47e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—melanoma	2.66e-06	1.46e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—melanoma	2.66e-06	1.46e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—melanoma	2.66e-06	1.46e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—melanoma	2.65e-06	1.46e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—melanoma	2.65e-06	1.45e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK1—melanoma	2.64e-06	1.45e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—melanoma	2.64e-06	1.45e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—melanoma	2.64e-06	1.45e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—melanoma	2.64e-06	1.45e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PRKCA—melanoma	2.64e-06	1.45e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—melanoma	2.63e-06	1.44e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—melanoma	2.63e-06	1.44e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CB—melanoma	2.63e-06	1.44e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—melanoma	2.62e-06	1.44e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—melanoma	2.62e-06	1.44e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—melanoma	2.62e-06	1.44e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—melanoma	2.62e-06	1.44e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—melanoma	2.61e-06	1.44e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—melanoma	2.61e-06	1.44e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ERCC2—melanoma	2.61e-06	1.43e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—melanoma	2.61e-06	1.43e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—melanoma	2.61e-06	1.43e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—melanoma	2.61e-06	1.43e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—melanoma	2.61e-06	1.43e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—melanoma	2.6e-06	1.43e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—melanoma	2.59e-06	1.42e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—melanoma	2.58e-06	1.42e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—melanoma	2.58e-06	1.42e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—melanoma	2.58e-06	1.42e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—melanoma	2.58e-06	1.41e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CB—melanoma	2.57e-06	1.41e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK3—melanoma	2.56e-06	1.41e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—melanoma	2.56e-06	1.4e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—melanoma	2.54e-06	1.4e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK3—melanoma	2.52e-06	1.38e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK3—melanoma	2.51e-06	1.38e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—melanoma	2.51e-06	1.38e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK3—melanoma	2.51e-06	1.38e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK3—melanoma	2.5e-06	1.37e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—melanoma	2.5e-06	1.37e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—melanoma	2.49e-06	1.37e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK3—melanoma	2.47e-06	1.36e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK3—melanoma	2.47e-06	1.35e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—melanoma	2.47e-06	1.35e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—melanoma	2.45e-06	1.34e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—melanoma	2.45e-06	1.34e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—melanoma	2.44e-06	1.34e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—melanoma	2.44e-06	1.34e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK1—melanoma	2.44e-06	1.34e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—melanoma	2.44e-06	1.34e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—melanoma	2.43e-06	1.33e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CB—melanoma	2.42e-06	1.33e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—melanoma	2.41e-06	1.32e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—melanoma	2.41e-06	1.32e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—melanoma	2.4e-06	1.32e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—melanoma	2.4e-06	1.32e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK1—melanoma	2.4e-06	1.32e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—melanoma	2.4e-06	1.32e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—melanoma	2.4e-06	1.32e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—melanoma	2.4e-06	1.31e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK1—melanoma	2.39e-06	1.31e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—melanoma	2.39e-06	1.31e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK1—melanoma	2.38e-06	1.31e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—melanoma	2.38e-06	1.31e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK1—melanoma	2.38e-06	1.3e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—melanoma	2.38e-06	1.3e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK1—melanoma	2.35e-06	1.29e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—melanoma	2.35e-06	1.29e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CD—melanoma	2.35e-06	1.29e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.35e-06	1.29e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—melanoma	2.35e-06	1.29e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—melanoma	2.34e-06	1.29e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—melanoma	2.34e-06	1.28e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—melanoma	2.33e-06	1.28e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ALB—melanoma	2.32e-06	1.27e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—melanoma	2.32e-06	1.27e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—melanoma	2.3e-06	1.26e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.29e-06	1.26e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—melanoma	2.27e-06	1.25e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—melanoma	2.26e-06	1.24e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—melanoma	2.26e-06	1.24e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—melanoma	2.26e-06	1.24e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—melanoma	2.25e-06	1.24e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—melanoma	2.24e-06	1.23e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—melanoma	2.23e-06	1.22e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—melanoma	2.22e-06	1.22e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—melanoma	2.22e-06	1.22e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—melanoma	2.22e-06	1.22e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—melanoma	2.22e-06	1.22e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—melanoma	2.22e-06	1.22e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—melanoma	2.18e-06	1.2e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—melanoma	2.13e-06	1.17e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—melanoma	2.12e-06	1.16e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—melanoma	2.12e-06	1.16e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—melanoma	2.12e-06	1.16e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—melanoma	2.11e-06	1.16e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—melanoma	2.09e-06	1.15e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.08e-06	1.14e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—melanoma	2.08e-06	1.14e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—melanoma	2.08e-06	1.14e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—melanoma	2.07e-06	1.14e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CG—melanoma	2.06e-06	1.13e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—melanoma	2.06e-06	1.13e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CB—melanoma	2.05e-06	1.12e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—melanoma	2.04e-06	1.12e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—melanoma	2.04e-06	1.12e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.04e-06	1.12e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—melanoma	2.03e-06	1.11e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—melanoma	2.03e-06	1.11e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—melanoma	2.01e-06	1.11e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—melanoma	2.01e-06	1.1e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—melanoma	2.01e-06	1.1e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—melanoma	2e-06	1.1e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—melanoma	2e-06	1.1e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—melanoma	1.99e-06	1.09e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—melanoma	1.98e-06	1.08e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—melanoma	1.97e-06	1.08e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—melanoma	1.97e-06	1.08e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—melanoma	1.96e-06	1.07e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—melanoma	1.96e-06	1.07e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—melanoma	1.92e-06	1.06e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—melanoma	1.92e-06	1.05e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—melanoma	1.91e-06	1.05e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—melanoma	1.91e-06	1.05e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—melanoma	1.89e-06	1.04e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—melanoma	1.88e-06	1.03e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—melanoma	1.87e-06	1.03e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—melanoma	1.87e-06	1.03e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—melanoma	1.84e-06	1.01e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—melanoma	1.84e-06	1.01e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—melanoma	1.83e-06	1.01e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—melanoma	1.83e-06	1e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CD—melanoma	1.81e-06	9.96e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—melanoma	1.81e-06	9.93e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—melanoma	1.8e-06	9.9e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ALB—melanoma	1.79e-06	9.83e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—melanoma	1.77e-06	9.72e-06	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—melanoma	1.73e-06	9.51e-06	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—melanoma	1.73e-06	9.48e-06	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—melanoma	1.7e-06	9.33e-06	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—melanoma	1.7e-06	9.32e-06	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—melanoma	1.7e-06	9.31e-06	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—melanoma	1.69e-06	9.28e-06	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—melanoma	1.68e-06	9.25e-06	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—melanoma	1.67e-06	9.16e-06	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—melanoma	1.66e-06	9.13e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—melanoma	1.6e-06	8.8e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CB—melanoma	1.58e-06	8.68e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—melanoma	1.57e-06	8.6e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—melanoma	1.56e-06	8.59e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—melanoma	1.47e-06	8.09e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—melanoma	1.37e-06	7.5e-06	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—melanoma	1.31e-06	7.19e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—melanoma	1.28e-06	7.02e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—melanoma	1.25e-06	6.86e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—melanoma	1.2e-06	6.61e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—melanoma	1.02e-06	5.6e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—melanoma	9.64e-07	5.29e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—melanoma	7.88e-07	4.32e-06	CbGpPWpGaD
